Abstract
Succinylacetone (SA) (4,6-dioxoheptanoic acid) is an abnormal metabolite produced in patients with hereditary tyrosinemia as a consequence of an inherited deficiency of fumaryl acetoacetate hydrolase activity. Patients with this disease are associated with a number of abnormalities, including aminoaciduria, proteinuria, liver failure, commonly hepatoma, and decreased GSH concentration in the liver. In the course of our studies of tyrosinemia, we found that the urine of patients with this disorder contains material(s) that absorbs light at 315 nm. We investigated the nature of the 315 nm material in detail. SA was found to react with amino acids and protein nonenzymatically, to form stable adducts at physiological temperature and pH. All SA adducts with amino acids and/or proteins exhibited an absorption peak at 315 nm. Although all amino acids reacted with SA, the most reactive amino acid was lysine (Lys), followed, in order, by glycine, methionine, phenylalanine, serine, alanine, and glutamine. SA- adducts were unstable at pH below 6, while they were made considerably more stable after reduction with NaBH4, suggesting that SA forms an adduct via Schiff base formation. High-performance liquid chromatography (HPLC) analysis of urines from patients with tyrosinemia revealed the existence of SA-glycine, SA-methionine, SA-tyrosine, and SA-phenylalanine. After digestion of urines with proteinase K, three more HPLC peaks appeared, which all corresponded to SA-Lys adducts. TLC analysis of SA-Lys showed that SA-Lys could form as many as seven different adducts. No SA-adduct peaks were observed in HPLC in urines from normal subjects, patients with other forms of aminoaciduria, or patients with the nephrotic syndrome. In addition to amino acids and proteins, SA reacted with reduced glutathione (GSH) and formed a stable adduct. These findings suggest that SA adduct formation with amino acids, GSH, and proteins is a significant process occurring in tyrosinemia, and may account for certain of the pathologic findings in this hereditary disorder.
Full Text
The Full Text of this article is available as a PDF (996.2 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Cerutti P. A. Prooxidant states and tumor promotion. Science. 1985 Jan 25;227(4685):375–381. doi: 10.1126/science.2981433. [DOI] [PubMed] [Google Scholar]
- Fällström S. P., Lindblad B., Steen G. On the renal tubular damage in hereditary tyrosinemia and on the formation of succinylacetoacetate and succinylacetone. Acta Paediatr Scand. 1981;70(3):315–320. doi: 10.1111/j.1651-2227.1981.tb16558.x. [DOI] [PubMed] [Google Scholar]
- Garlick R. L., Mazer J. S. The principal site of nonenzymatic glycosylation of human serum albumin in vivo. J Biol Chem. 1983 May 25;258(10):6142–6146. [PubMed] [Google Scholar]
- Gentz J., Lindblad B., Lindstedt S., Levy L., Shasteen W., Zetterstrom R. Dietary treatment in tyrosinemia (tyrosinosis). With a note on the possible recognition of the carrier state. Am J Dis Child. 1967 Jan;113(1):31–37. doi: 10.1001/archpedi.1967.02090160081006. [DOI] [PubMed] [Google Scholar]
- Grenier A., Lescault A., Laberge C., Gagné R., Mamer O. Detection of succinylacetone and the use of its measurement in mass screening for hereditary tyrosinemia. Clin Chim Acta. 1982 Aug 4;123(1-2):93–99. doi: 10.1016/0009-8981(82)90117-6. [DOI] [PubMed] [Google Scholar]
- HALVORSEN S., GJESSING L. R. STUDIES ON TYROSINOSIS: 1, EFFECT OF LOW-TYROSINE AND LOW-PHENYLALANINE DIET. Br Med J. 1964 Nov 7;2(5418):1171–1173. doi: 10.1136/bmj.2.5418.1171. [DOI] [PMC free article] [PubMed] [Google Scholar]
- LOWRY O. H., ROSEBROUGH N. J., FARR A. L., RANDALL R. J. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951 Nov;193(1):265–275. [PubMed] [Google Scholar]
- Lindblad B., Lindstedt S., Steen G. On the enzymic defects in hereditary tyrosinemia. Proc Natl Acad Sci U S A. 1977 Oct;74(10):4641–4645. doi: 10.1073/pnas.74.10.4641. [DOI] [PMC free article] [PubMed] [Google Scholar]
- MOORE S., STEIN W. H. A modified ninhydrin reagent for the photometric determination of amino acids and related compounds. J Biol Chem. 1954 Dec;211(2):907–913. [PubMed] [Google Scholar]
- Manabe S., Bucala R., Cerami A. Nonenzymatic addition of glucocorticoids to lens proteins in steroid-induced cataracts. J Clin Invest. 1984 Nov;74(5):1803–1810. doi: 10.1172/JCI111599. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Pongor S., Ulrich P. C., Bencsath F. A., Cerami A. Aging of proteins: isolation and identification of a fluorescent chromophore from the reaction of polypeptides with glucose. Proc Natl Acad Sci U S A. 1984 May;81(9):2684–2688. doi: 10.1073/pnas.81.9.2684. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Sassa S., Kappas A. Hereditary tyrosinemia and the heme biosynthetic pathway. Profound inhibition of delta-aminolevulinic acid dehydratase activity by succinylacetone. J Clin Invest. 1983 Mar;71(3):625–634. doi: 10.1172/JCI110809. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Stoner E., Starkman H., Wellner D., Wellner V. P., Sassa S., Rifkind A. B., Grenier A., Steinherz P. G., Meister A., New M. I. Biochemical studies of a patient with hereditary hepatorenal tyrosinemia: evidence of glutathione deficiency. Pediatr Res. 1984 Dec;18(12):1332–1336. doi: 10.1203/00006450-198412000-00023. [DOI] [PubMed] [Google Scholar]
- Tschudy D. P., Hess R. A., Frykholm B. C. Inhibition of delta-aminolevulinic acid dehydrase by 4,6-dioxoheptanoic acid. J Biol Chem. 1981 Oct 10;256(19):9915–9923. [PubMed] [Google Scholar]
- Weinberg A. G., Mize C. E., Worthen H. G. The occurrence of hepatoma in the chronic form of hereditary tyrosinemia. J Pediatr. 1976 Mar;88(3):434–438. doi: 10.1016/s0022-3476(76)80259-4. [DOI] [PubMed] [Google Scholar]